Strontium ranelate: new data on fracture prevention and mechanisms of action.
Osteoporosis treatments need to combine an unequivocally demonstrated reduction of fractures, at various skeletal sites, long-term safety, and a user-friendly profile that optimizes therapeutic adherence. Strontium ranelate is the first compound to simultaneously decrease bone resorption and stimulate bone formation. Its anti-fracture efficacy at various skeletal sites has been established for as long as 5 years through studies of the highest methodological standards. Increases in bone mineral density observed after 1 year of treatment are predictive of the long-term fracture efficacy, suggesting for the first time in osteoporosis that bone densitometry can be used as a monitoring tool. Due to a positive risk/benefit ratio, strontium ranelate is now considered as a first-line treatment in the management of osteoporosis.
Reginster
Jean-Yves
JY
Bone and Cartilage Metabolism Research Unit, CHU Centre-Ville, Policliniques L. BRULL, 4020 Liege, Belgium. jyreginster@ulg.ac.be
Deroisy
Rita
R
Neuprez
Audrey
A
Hiligsmann
Mickaël
M
Zegels
Brigitte
B
Bruyere
Olivier
O
D050071:Bone Density Conservation Agents / Q000494:pharmacology*; D050723:Fractures, Bone / Q000517:prevention & control*; D006801:Humans; D009942:Organometallic Compounds / Q000494:pharmacology*; D010024:Osteoporosis / Q000188:drug therapy*; D013876:Thiophenes / Q000494:pharmacology*; D016896:Treatment Outcome
D050071:Bone Density Conservation Agents; D009942:Organometallic Compounds; D013876:Thiophenes; C081587:strontium ranelate